DuraSite

DuraSite®

Ophthalmology A sustained-release system designed to permit the gradual release of a drug into the eye over a period of hrs, overcoming problems common with conventional drug delivery
References in periodicals archive ?
Ophthalmologic company InSite Vision (Other OTC:INSV) reported on Wednesday the receipt of the US Patent Number 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite from the US Patent and Trademark Office (USPTO).
ISV-401 combines azithromycin with DuraSite, the company's patented drug-delivery vehicle that offers the benefits of prolonged release of an active ingredient.
According to the company, DexaSite is an investigational product that combines a low dose of the corticosteroid dexamethasone with its proprietary DuraSite drug delivery platform.
Ophthalmic products company Senju Pharmaceutical Co revealed on Tuesday the launch of a collaboration and license agreement to develop and market InSite Vision's (Other OTC:INSV) azithromycin ophthalmic solution using DuraSite including AzaSite 1% and AzaSite Xtra 2% ocular antibiotics in Japan.
M2 EQUITYBITES-June 5, 2014-InSite Vision awarded USPTO's Notice of Allowance for Bromfenac formulations in DuraSite, BromSite, ISV-101 & BromDex
M2 PHARMA-June 5, 2014-InSite Vision awarded USPTO's Notice of Allowance for Bromfenac formulations in DuraSite, BromSite, ISV-101 & BromDex
075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with its DuraSite drug delivery technology.